These effects on the insulin/Akt/mTOR signalling suggest that it may be possible to test GmA as a potential treatment for other degenerative diseases linked to downregulation of this signalling system, such as heart failure and osteoarthritis [15, 16, 17]. This evidence concerns the gene AKT1 and neurodegenerative disease.